BridgeBio Oncology Therapeutics, Inc. (BBOT) News
Track canonical SquawkNews coverage tagged to BBOT, BridgeBio Oncology Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BBOT Reports Inducement Grants
BBOT reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Aug 11, 2026, 08:40 PM UTC
L
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
BridgeBio Oncology (NASDAQ: BBOT ) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over losses of $(566.46) pe
EARNINGS | Aug 11, 2026, 08:39 PM UTC
L
BBOT - BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
BBOT - BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
EARNINGS | Aug 11, 2026, 08:08 PM UTC